However, since TIM3+ Tregs constitute the major fraction of tumor‐infiltrating Tregs and provide the bulk of tumor immunosuppressive activity, permitting tumor progression in vivo,[39] it is intriguing to suggest that galectin‐9 has a predominant suppressive rather than promotional effect on Tregs, as we have observed. The gene discussed is HAVCR2; the disease is neoplasm.